Plus   Neg

Seattle Genetics, Astellas Submit BLA For Enfortumab Vedotin - Quick Facts

Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (ALPMY,ALPMY) have submitted a Biologics License Application to the U.S. FDA for the accelerated approval of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer.

Enfortumab vedotin, an investigational antibody-drug conjugate, targets Nectin-4, a protein that is highly expressed in urothelial cancers. The BLA submission was based on results from the first cohort of patients in the EV-201 phase 2 trial. Based on preliminary results from a phase 1 trial, the FDA previously granted enfortumab vedotin Breakthrough Therapy designation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration or FDA announced on its website that pharma major Pfizer, Inc. issued recall of two lots of tablets meant to treat acute migraine in adults for concerns over bacteria infection. The pharma company is recalling two lots of Relpax (eletriptan hydrobromide) 40 mg tablets for potential presence of Genus Pseudomonas and Burkholderia bacteria. Cosmetics company Revlon Inc. (REV) is reportedly considering a potential sale of parts or all of its business. According to Bloomberg, Revlon has retained financial advisers from Goldman Sachs Group Inc. to explore strategic alternatives. No deal has been reached yet, but Revlon is exploring all... China's Lenovo Group Ltd. warned it may have to raise prices of its products if the U.S. moves ahead with the decision to impose additional tariffs on Chinese goods, according to a report by Reuters. The warning by Lenovo, the world's largest PC maker, comes amid the escalating trade war between the U.S. and China that has raised concerns about the global economic outlook.
Follow RTT